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the recombinant protein, which can be applied to other membrane proteins reluctant to expression,
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crystallization. Focusing on expression in a soluble and functional state, in a detergent environment, is the key
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Despite important efforts made in the last ten years, solving a
membrane protein structure still remains a challenge. A universal and
efﬁcient method for the production of membrane proteins dedicated to
structural studies does not exist. To overcome this severe bottleneck,
progresses have resided in building up robust and rationale strategies
that i) facilitate the exploration of large number of expression systems
(including eukaryotic cells) [1], ii) improve their efﬁciency [2–4] iii)
introduce novel surfactants and iv) extend crystallization to innovative
methods (i.e. lipidic phases) [5,6]. In parallel, automation and
miniaturization introduced by the structural genomic programs help
in screening large number of conditions from expression to crystalliza-
tion with limited amounts of proteins. Such tools contributed to recent
successes in membrane proteins structures. Cell-free expression
introduced in the eighties as an alternative approach to bacterial
expression [7] is an attractive way for obtaining high yield protein
production. The method is interesting as any additional compounds
such as lipids or surfactants can easily be supplemented to the reaction
medium. Several groups have already optimized the cell-free systems
for different types of membrane protein: channels, G protein-coupled
receptors, transporters, … [8–10]. Currently, selenomethionine EmrE
used to determine phases is the only published example of crystalliza-
tion for a cell-free expressedmembrane protein [11]. Therefore, in vitroprotein synthesis is promising for membrane protein structures, but no
report has yet described the way from gene to crystals so far.
VDAC is the main outer mitochondrial membrane protein. It is
involved in the exchange of metabolites between the cytosol and the
inter-membrane space but a better understanding of its molecular
mechanism requires detailed structural information. Mannella's team
was the ﬁrst to study the structure of VDAC at low resolution by
electron microscopy [12]. Then, two-dimensional crystals [13] or
atomic force microscopy [14,15] provided low-resolution structural
information of the protein and its arrangement in the native
membrane. High-resolution structures of mouse and human VDAC
have only been solved by the end of 2008 [16–18], and revealed an
unpredicted 19 strands β-barrel. In these three studies, VDAC has
been overexpressed in inclusion bodies in Escherichia coli and then
refolded after solubilization in guanidinium. As described in the
literature the optimization from refolding to exploitable-crystals of
VDAC in detergent took more than ten years [13,19], demonstrating
the difﬁculty of crystallizing VDAC.
The expression of VDAC by a cell-freemethod described herein, is an
innovative approach inmembrane protein crystallization extendable to
othermembrane proteins. Our strategy is to directly express the protein
in the presence of a detergent compatible with the crystallization in
order to obtain a soluble, functional and crystallizable protein. We
obtained VDAC in nearly mg quantities per 3 ml of cell-free synthesis
reaction. Combining a one-step puriﬁcation, nanodrop crystallization
and in-drop diffraction screens led to X-ray diffracting-VDAC crystals in
six different detergents, therefore demonstrating the potential use of
the cell-free method for other membrane proteins.
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2.1. Materials
All chemicals, except the detergents, were from Sigma. Detergents
were from Anatrace at anagrade quality level.
2.2. hVDAC1 expression and puriﬁcation
Human VDAC-1 sequence was cloned in the pIVEX2.4b from Roche
by using NdeI and XhoI restriction enzymes. The following primers
were designed to clone hVDAC1: hVDAC1for GGAATTCCATATGG-
CTGTGCCACCCACGT, hVDAC1rev TAGGACTGGAATTTCAAGCATAACT-
CGAGTAACGC. Expression was performed with the Roche RTS 100
(small volume batch system) and RTS 500 (medium scale with
continuous exchange by dialysis) kits and the mixture was incubated
in the Eppendorf Thermomixer comfort device. Initial screens were
done in 50 µl volume RTS 100 E. coli lysate, substrate mix, amino acids
mix, Roche reconstitution buffer were mixed with 1 µg of plasmidic
DNA and the desired detergent. The mixture is incubated for 6 h and
then centrifuged 10 min at 15,000 g. Supernatant and pellet proteins
were loaded and separated on 10% SDS-PAGE gel, transferred to
nitrocellulose membrane and revealed with HRP conjugated anti-His
antibody (Sigma) on a Kodak 4000MM image station. Quantiﬁcation
was done with the molecular imaging software (Kodak). RTS500
expression has been done in 1 to 5 ml reactionmix. In the reaction and
feeding mix, EDTA-free protease inhibitors (Roche) and detergents
were added. Typically, 0.2% of β-DDM was used. In the reaction mix,
15 µg of DNA was also added per ml of reaction mix. The reaction was
started for 48 h at 20 °C with shaking of 900 rpm. At the end of the
expression, the reaction mix solution was centrifuged for 30 min at
100,000 g (Beckman Coulter-TLA100.3 rotor). The supernatant was
recovered, diluted four times in 50 mM Tris pH 7.5, 0.5 M NaCl, 0.1%
β-DDM, 10 mM imidazole, and mixed with 1 ml of Ni-NTA resin
(Qiagen) preequilibrated in this last buffer. After a 2 h incubation at
4 °C of this mixture, the resin was washed three times with 20 mM
Tris pH 7.5, 0.5 M NaCl, 0.05% β-DDM (or the new detergent when
exchanged was performed) and increasing imidazole concentration
(10, 20 and 50 mM). hVDAC1 was then eluted in the same buffer with
500 mM imidazole. Inﬂuence of cholesterol on the diffraction power
of the crystals was assayed by addition of 0.1 to 1% of cholesterol
(w:v) in all buffers from expression mix to crystallization buffer.
Puriﬁcation of aggregated forms of VDAC was done by solubilizing
the pellet from ultracentrifugation by 1% of β-DDM during 12 h. Then,
the protein was puriﬁed in the same way as for the soluble form of
cell-free expressed VDAC.
VDAC expressed in cell-free wheat germ extract was produced
using RTS100 and RTS500 kits from Roche. Both are continuous
dialysis exchange systems. Detergent choice and concentration
optimization were done with the RTS100 kit in 50 µl reaction volume
and 500 µl feeding volume. Large-scale experiments were done with
the RTS500 kit in similar conditions as the ones used for bacterial
extract except that only 0.04% of β-DDMwere used during expression.
The puriﬁcation procedure is the same as the one used for the
bacterial extract.
For crystallization the buffer is exchanged on a PD10 column
(GE-healthcare) for 20 mMTris pH 7.5, 50 mMNaCl, 0.05% β-DDM (or
the exchanged detergent at the desired concentration). Then, the
protein was concentrated up to 5 to 15 mg/ml in amicon concentrator
(30 kDa cut-off), concentration determined by UV absorbance
(ε280=39,000 M−1 cm−1). Finally, the tag was cleaved by using 1 U
of factor Xa per 150 µg of pure hVDAC1. Gel ﬁltration of Ni-NTA
puriﬁed hVDAC1 was performed by loading 250 µl of sample on a
20 ml superdex-200 column (GE-healthcare). The chromatography
was performed at 0.4 ml/min in 20 mM Tris pH 7.5, 50 mM NaCl and
0.05% β-DDM.2.3. SDS-PAGE analysis
All steps were carried at 20 °C. 10 µl of protein samples were
mixed with 2 µl of SDS-PAGE loading buffer (0.35 M Tris–HCl pH 6.8,
30% glycerol (w/v), 10% SDS (w/v), 0.6 M β-mercaptoethanol, 0.01%
bromophenol blue) just before running the gels. Proteins were
separated on 10% acrylamide SDS-PAGE gels and transferred onto
nitrocellulose membrane (Biorad) when necessary. Protein gels were
stained by Coomassie blue R250.
2.4. Electrophysiology
Giant proteoliposomes were prepared as described in [8] with few
modiﬁcations. 1 μg of pure hVDAC1 was added to 2 ml of 100 mM KCl,
1 mg/ml asolectin, 10 mM Hepes (pH 7.4). After 20 min equilibration at
room temperature, 320 μg of SM2 Bio-Beads (Bio-Rad)were added to the
solution and incubatedovernight at4 °C to remove thedetergent. TheBio-
Beads having settled to the bottom, the supernatant was removed and
centrifuged 25 min at 90,000 rpm (Beckman centrifuge, rotor TLA 100.3).
The pelletwas resuspended in 15 μl 10 mMHepes (pH 7.4). To formgiant
liposomes, a single cycle of dehydratation/rehydratation was performed
by drying 7 µl of sample under vacuum and resuspending in 15 µl of
100 mM KCl, 10 mM Hepes (pH 7.4).
For patch-clamp recordings, 7 μl sample of giant liposomes were
deposited in a Petri dish used as a patch-clamp chamber. The chamber
was then ﬁlled with 7 ml of 100 mM KCl, 10 mM Hepes (pH 7.4).
Channel activity was recorded using the patch-clamp technique in the
inside-out conformation [20]. Patch pipettes were pulled from
borosilicate capillaries to a resistance of about 5–10 MΩ and were
ﬁlled in with a solution containing 100 mM KCl, 5 mM MgCl2, 2 mM
CaCl2 and 10 mM Hepes (pH 7.4). The currents were recorded using a
Biologic RK-300 ampliﬁer, ﬁltered at 300 Hz, sampled at 1 kHz and
analysed with Clampﬁt 10 (Axon) [21].
2.5. Limited proteolysis assays and analysis
Pure hVDAC1 at 1 mg/ml was mixed with proteases (chymotryp-
sin, trypsin, elastase, subtilysin, thermolysin or papain) at a weight-
to-weight ratio between 1:100 and 1:1000. The limited proteolysis
was started by adding protease to VDAC solution and kinetics were
stopped by adding 3 µl of SDS-PAGE loading buffer. Limited
proteolysis results were analysed by SDS-PAGE gels and N-terminal
sequencing was done after transfer of the protein on PVDFmembrane.
The protein bands were cut from the membrane and sequenced by
automated Edman degradation on an Applied Biosystems gas-phase
sequencer, model 477A, with on-line analysis of the phenylthiohy-
dantion derivatives.
2.6. Crystallization–crystallography
Initial screens, salt, and additive screens were performed in 96
well-plate hanging-nanodrops (Greiner). For a 100 µl reservoir, the
drops were made of 100 nl of protein supplemented with 100 nl of
reservoir. QIAgen commercial screens were initially used (The
classics, CS Lite, PEG/Ion, MembFac, Natrix, Quickscreen, Grid screens,
The classics II). Salt and additive screens from Hampton were added
directly to the reservoir in 96 well-plates. Manual optimizations were
carried out with dropsmade of 1 µl of protein plus 1 µl of reservoir, for
a 500 µl reservoir. Lipids assayed as additives were added to the
protein just before setting-up the crystallization drops [22]. Best
crystals of hVDAC-1 in β-DDMwere obtained in 17–18% PEG550MME,
100 mM Tris pH8.5, 200 mMKNitrate and inα-DDMwere obtained in
22–23% PEG550MME, 100 mM Tris pH 8.5, 100–200 mM KNitrate.
Dehydration and cross-linking post-crystallization treatments
have been done according to the different procedures developed
and described in [23].
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crystallization plates directly into the beam on the BM30A beamline
at the ESRF [24]. For diffraction screens and data collections, crystals
were harvested, plunged into mother liquor containing 10% of
glycerol as cryoprotectant if necessary and ﬂash frozen in liquid
nitrogen. Diffraction data were collected at 100 K on ID14eh1,
ID14eh2, ID14eh3, ID14eh4, ID23eh1, ID23eh2 and ID29 beamlines
at the ESRF Grenoble.
3. Results
3.1. Expression–puriﬁcation
ThehumanVDAC1 (hVDAC1)was expressed in a commercial cell-free
E. coli extract (Roche). The construct contains a cleavable N-terminal
hexahistidine tag. hVDAC1 expression was assayed in the absence or in
the presence of different detergents in order to directly obtain a soluble,
folded and functional form of the protein. The detergents were chosen
among thosewhich have already proven to be successful in crystallization
(http://www.mpdb.ul.ie/ [25]). However, detergents already known to
strongly inhibit the protein synthesis, such as β-OG [8], were excluded. In
a ﬁrst attempt, expression conditions were optimized in small volumes
(25–50 µL) with 6 h expression time and analysed by Western-blotting.
Two criteria have been taken into account: the yields of total expression
and of the soluble fraction (Fig. 1a). In the absence of detergent the
expression yield exceeded 1 mg/ml of aggregated hVDAC1 (data not
shown). By exploring the temperature and different detergents, the
quantity of protein expressed in a soluble form varied. The temperature
was optimized with the most commonly used detergent β-DDM.
Decreasing the temperature from 30 °C to 20 °C allowed an important
decrease of the aggregation of hVDAC1 during the expression (data notFig. 1. Expression and crystallization screenings. Panel a, quantiﬁcation of the total, soluble
independent experiments. Panel b, SDS-Page gel of pure hVDAC1 expressed without proteashown). Then, the choice of the best detergent compatible with the
expression of a high amount of protein in a soluble formwas done. Seven
different detergents have been tested with concentrations ranging from
0.1 to 0.2% for low cmc detergents (C12E8, β-DDM, α-DDM, LDAO,
foscholine-12), 0.4% for cymal-5 and 1% for C8E4. In LDAO and cymal-5,
hVDAC1 was not or almost not expressed, respectively (Fig. 1a).
Expression was low in the presence of C8E4 or α-DDM. In C12E8, large
expression of VDAC was detectable but in an aggregated form (Fig. 1a).
Only two detergents gave interesting results: β-DDM and foscholine-12,
in which hVDAC1 was highly expressed with a large amount of soluble
protein (Fig. 1a). Because there is little crystallization experience with
foscholine-12, β-DDM has been chosen for the scale-up experiments.
Expression time and detergent quantity were optimized in a 1 ml
reaction chamber with continuous exchange by membrane dialysis.
Although large aggregates of hVDAC1 started to appear after 36 to
48 h expression in the presence of 0.1–0.2% β-DDM, the yield of
expression still increased after 48 h (data not shown). The best
expression conditions of soluble hVDAC1 were 48 h at 20 °C in the
presence of 0.2% β-DDM. The aggregates of hVDAC1 were removed by
ultracentrifugation at the end of the expression reaction. hVDAC1was
puriﬁed in one-step Ni-NTA chromatography (Fig. 1b) with a fold
similar to the native protein, as shown by circular dichroism (data not
shown). The functionality of pure hVDAC1 was assayed by patch-
clamp after reconstitution in giant liposomes. Single channel currents
could be observed at both positive and negative membrane potentials
(Fig. S1a). Recordings were characterized by the presence of multiple
conductance levels, the most frequently being around 225pS and the
largest around 450pS (Fig. S1b). These values match those described
previously in the literature for native VDAC [26]. Crystallization assays
of hVDAC1were donewith a nanodrop crystallization robot by testing
288 conditions from Qiagen screens. Although initial crystals wereand aggregated expression of hVDAC1 in different detergents. Data are means of 2 to 4
se inhibitor. Panel c, initial hVDAC1 crystals in nanodrops. Scale bar: 100 μm.
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solution have been required to circumvent the non-reproducibility of
these crystals.
3.2. Biochemical optimizations for the crystallization
Obtaining good-quality membrane protein crystals crucially
depends on the purity, conformational homogeneity and monodis-
persity of the protein. These three pointswere optimized to reproduce
initial crystals.
hVDAC1 puriﬁed in a single step in the presence of β-DDM
sometimes appeared as a double band on SDS-PAGE gels (Fig. 1b). The
lower band is the consequence of proteolysis during expression,
because the addition of protease inhibitors to the cell-free extract at
the beginning of the production resulted in its disappearance.
However, this pure and homogenous VDAC did not crystallize.
Conformational heterogeneity can be induced by ﬂexible parts of
the protein that might hamper crystallization [27]. Limited proteolysis
assays were then used to identify a rigid core of hVDAC1, favourable to
crystallization. Thermolysin, trypsin and chymotrypsin principally led
to the cleavage of the tag just after the factor Xa site (Fig. 2a and S2), as
revealed by N-terminal sequencing. Other proteolysis products of
hVDAC1, around 20 kDa, were obtained with trypsin (Fig. 2a, lane 3–5
and Fig. S2) and in a lower extent with elastase (data not shown),
starting at residues 114 and 107, respectively (Fig. S2). Thus, limited
proteolysis demonstrated that, apart from the tag, cell-free expressed
hVDAC1 has a rigid core. Cleavage of the tag with factor Xa led to
reproducible crystals. The presence in the crystals of hVDAC1 without
histidine tag was conﬁrmed by N-terminal sequencing.
Size exclusion chromatography after cleavage increased the
sample purity by removing the factor Xa, the cleaved histidine tag,
as well as few aggregates and other contaminants (Fig. 2b and c).
hVDAC1 was eluted as a well-shaped peak with an elution volume
around 12 ml (Fig. 2c) indicative of monodispersity (Fig. 2c), which is
favourable for crystallization. Nonetheless, the use of a desalting
column instead of a superdex-200 gave similar results (Fig. 2d), and
both puriﬁcation procedures led to crystals with similar diffraction
powers. Therefore, desalting columnwas chosen for the limited loss of
protein and time in comparison to gel ﬁltration.Fig. 2. Puriﬁcation and characterization of cell-free expressed VDAC. Panel a, Limited proteolys
30 min and 2 h time-point of the kinetic of hVDAC1 trypsinolysis, lane 6 to 8: 15 min, 30 min an
puriﬁcation. Lane 1: molecular markers, lane 2: total expression, lane 3: aggregated proteins e
imidazolewash, lane 7:Ni-NTA elution, lane 8: FactorXa cleavage, lane 9: pure hVDAC1 after sup
on superdex-200. Panel d, Size exclusion chromatography of desalted proteins on superdex-20Within two days, 200 to 300 µg of pure and “ready to crystallize”
hVDAC1 solubilized in β-DDM at a concentration of 10 mg/ml
(Fig. 2b), were obtained per ml of cell-free extract reaction.
3.3. Crystallization optimizations
hVDAC1 crystals are not well-ordered as seen from the rapid
decrease in intensity as a function of resolution (Fig. 3a, left panel) and
diffracted anisotropically to a maximum of about 12 Å (Fig. 3a). To
improve the crystal quality additives including salts and detergents
were screened in nanodrop crystallization assays. Diffraction quality
was assayed directly from crystals in the nanodrops in which they
grew by using a speciﬁc device designed on the BM30A beamline at
the ESRF [24]. These crystallization and diffraction technologies
allowed to screen hundred crystallization conditions by assessing
the diffraction power of the crystals and circumvented the limited
quantity of pure hVDAC1. Additive screens highlighted the use of
potassium nitrate and spermidine or methanol to improve crystal
quality. Detergent screened as additives led to crystals with almost all
maltosides and with some other detergents without any signiﬁcative
improvement in diffraction. Scaling up the optimized conditions gave
well-shaped β-DDM-hVDAC1 crystals and their size was increased by
seeding (Fig. 3b). Other post-crystallization treatments such as
dehydration or cross-linking importantly decreased the diffraction
power. Addition of lipids, especially cholesterol, either in the
crystallization drops or during all the process from expression to
crystallization never improved the crystal quality. Finally, the best
hVDAC1 crystals in β-DDMwere cryoprotectedwith 15% of glycerol or
with paraffin oil diffracted X-rays isotropically down to 8 Å (Fig. 3c).
Several recent successes in membrane protein crystallization have
been obtained by exchanging the detergent to another in order to obtain
new crystal forms or better crystal packing, with improved diffraction
[28]. Exchange of β-DDM forα-DDM, β-undecylmaltoside (UDM), LDAO,
C8E4, C12E8, cymal-5, cymal-6 and cymal-7 was performed on Ni-NTA
resin. Several crystallizationconditions (192sparseandaround20derived
from the crystallization in β-DDM) were assayed for each detergent.
Crystals were obtained with 5 other detergents: C8E4 (Fig. 4a), cymal-6
(Fig. 4b— left panel), UDM (Fig. 4b — right panel), cymal-7 (not shown)
and α-DDM (Fig. 4c). Although C8E4 led to crystals in several conditions,is of pure hVDAC1. Lane 1: molecular markers, lane 2: pure hVDAC1, lane 3 to 5: 15 min,
d 2 h time-point of the kinetic of hVDAC1 chymotrypsinolysis. Panel b, Analysis of hVDAC1
xpressed, lane 4: soluble proteins expressed, lane 5: Ni-NTA ﬂow-through, lane 6: 50 mM
erdex-200 gelﬁltration. Panel c, Size exclusion chromatographyofNi-NTA elutedproteins
0.
Fig. 3. Optimized crystals and diffraction of crystals of hVDAC1 in β-DDM. Panel a,
diffraction images at 0° and 90° of an initial crystal of hVDAC1 in β-DDM. Panel b,
crystals of cleaved hVDAC1 in β-DDM after optimization of the conditions. Scale bars:
100 µm. Panel c, diffraction image of optimized crystals of hVDAC1 in β-DDM.
Fig. 4. Crystals of hVDAC1 in different detergents and diffraction of crystals in α-DDM.
Panel a, crystals of hVDAC1 in C8E4. Panel b, microcrystals of hVDAC1 in cymal-6 (left
picture) and plate crystals in UDM (right picture). Panel c, optimized crystal of hVDAC1
inα-DDM (left picture) and crystals of hVDAC1 inα-DDM in nanodrops (right picture).
Panel d, diffraction images at 0° and 90° of an optimized crystal of hVDAC1 in α-DDM.
Scale bars: 100 µm.
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conditions than C8E4, while cymal-6, cymal-7 and α-DDM crystallized in
conditions deriving from that of β-DDM one. In UDM, hVDAC1 crystals
diffracted to less than 20 Å. In cymal-6, hVDAC1 crystallized as very small
rods, which after optimization diffracted only at very low resolution
(30 Å). In cymal-7, hVDAC1 crystallized in the same form and in the same
conditions than inβ-DDMbutdiffractedpoorly (30 Å). After optimization,
hVDAC1 crystals obtained with α-DDM, diffracted slightly better than
with β-DDM in termof resolution and isotropy (Fig. 4d). Space group and
cell parameters derived from the diffraction data (Table 1) suggest that
hVDAC1 inα-DDM and in β-DDM crystallizes in the same space group as
in [16], but with larger unit cell parameters, mainly along the c-axis.
4. Discussion
Although VDAC structures have recently been described [16–18], the
use of cell-free expressedmembrane protein in the presence of detergent
has never been reported for crystallization. Thus, the successful
crystallization of human VDAC1 described herein, even with limited
diffraction, proves that a large majority of the produced protein is well
folded anddemonstrates that detergent cell-free expressionofmembrane
proteins is useful for structural studies. It is therefore noteworthy to
highlight the advantages and the capabilities of this approach and to
compare cell-free hVDAC1 crystals with the previously published ones.4.1. Advantages of the method
Cell-free expression of membrane proteins presents many beneﬁts
compared to all other expression systems. First of all, the simplicity
Table 1
Unit cell parameters of VDAC in β-DDM- or in α-DDM and parameters of the crystals
obtained in cymal-5 [16]. In the three cases, the space group is P321.
Detergent a (Å) b (Å) c (Å) Diffraction limit (Å)
β-DDM 90 90 192 8
α-DDM 77 77 173 7
Cymal-5 from [16] 78 78 167 4.1
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membrane protein along with a single puriﬁcation step render this
approach very attractive for crystallographic studies. Indeed, in the
case of VDAC, only one to two months were required to go from the
cloning to the pure protein, and diffracting crystals were obtained in
less than six months. However, the time frame to go from gene to
structure of any membrane protein would be different but always
faster with cell-free expression than with any other expression
method.Moreover, the strategy optimized for VDAC expression can be
directly transferred to other membrane proteins. Indeed, for several
membrane proteins tested in our laboratory, expression time between
24 and 48 h is optimal and reducing the temperature down to 20 °C is
a prerequisite to obtain a good fraction of soluble protein in the
presence of a surfactant. Due to residual bacterial proteases in the
lysate, the use of protease inhibitors is also crucial to obtain a
full-length protein after expression. Only the detergent has to be
speciﬁcally chosen according to the level of expression and the quality
of each protein. It is also noteworthy that cell-free expression allows
to screen, for tens of different amphiphiles, the expression level and
the solubility of a membrane protein in only two days. Similarly,
several detergents can be explored by on-column exchange, in order
to select the most appropriate for stabilizing and/or crystallizing the
protein.
Secondly, the expression level of the system is insensitive to many
factors. It is possible to express toxic proteins, which is a frequent
characteristic of membrane proteins. Mutations, truncations and/or
insertions have in general a minor effect on the expression level, as
observed for three VDAC constructs with loop and β-strand deletions
(data not shown). As long as they do not interfere with the transcription
and/or translation process, it is possible to add various compounds in the
expression mix. It can be a speciﬁc ligand or lipid that could help in the
folding and/or could block a single conformation for the crystallization
(i.e. addition of cholesterol was assayed in this study). This technique also
allows to produce a labelled-protein, for NMR study [29] or crystallo-
graphic phasing, without important production decrease [30]. Moreover,
seleno-methionine and/or -cysteine labelled protein expression is easily
performed in this system and does not require the use of speciﬁc strains.
Finally, the cost of speciﬁcally-labelled protein production or the
addition of ligands is reduced in cell-free system due to the small
reaction volume (1 ml compared to 1 l).
4.2. Discussion of other cell-free expression concepts previously
published
Frank Bernhard's group has intensively studied cell-free expres-
sion [10] of differentmembrane proteins, including G protein-coupled
receptors (GPCR) [31]. Their constraints are different from ours, as
they express proteins mainly for NMR. The idea developed in this
manuscript is to obtain in one step the membrane protein in a soluble
and functional form surrounded by a detergent compatible with
crystallographic studies. NMR does not necessarily require homoge-
neous detergent belts around the protein. Therefore, among their
favoured detergents they also consider not-chemically well-deﬁned
molecules (i.e. Brij). They also work on detergent-resolubilized
aggregated protein synthesized in the absence of surfactants. It is
known that such proteins display a conformational variability that
hampers crystallization. Indeed, we have attempted the puriﬁcation ofhVDAC1-aggregated form. The pellet has been solubilized in different
detergents. In the best cases, after puriﬁcation the quantity of protein
obtained was comparable to the one obtained after puriﬁcation of the
protein expressed in a soluble form. However, the crystallization of the
resolubilized hVDAC1 only led to microcrystals that very poorly
diffracted X-rays, illustrating the probable presence of slightly
misfolded proteins.
Other cell lysates can also be explored for the cell-free expression.
Kaiser et al. expressed functional GPCRs from wheat germ extracts
[32]. Indeed, the folding of eukaryotic proteins in wheat germ extract
could be facilitated by the presence of chaperones and co-factors not
present in E. coli. This alternative expression has also been tested for
hVDAC1. However, the expression level in wheat germ extract was
found to be more sensitive to detergents than compared to the E. coli
lysate. To circumvent this problem, the quantity of detergent such as
β-DDM or cymal-5 has been decreased down to 2 to 4 cmc. But, this
affected the quantity of soluble-expressed hVDAC1. Finally, pure
hVDAC1 was obtained in low quantity, ten times less than from E. coli
extracts. The crystallization of wheat germ expressed hVDAC1 led to
microcrystals with poor diffraction.
4.3. Comparison with previously published VDAC crystallization
Three VDAC structures have recently been published [16–18], all
based on VDAC expressed in E. coli inclusion bodies followed by a
refolding procedure. The work done by the group of Zeth is the closest
to ours, since VDAC has been crystallized from detergent solution [16].
The authors have tested many detergents [33] and obtained their best
crystals in cymal-5 (4 Å). In DDM their crystals did not diffract better
than 20 Å. It is interesting to notice that, in our study, VDAC did not
crystallize in cymal-5, but led to crystals in ﬁve different maltoside
detergents. The best crystals diffracted down to 7 Å in β-DDM and 6 Å
in α-DDM. A comparison detergent by detergent shows that the
proteins expressed in E. coli and refolded from inclusion bodies or
expressed in the cell-free system behave very differently in crystal-
lization. This demonstrates once again the interest of the method
described herein as it opens a new ﬁeld of exploration. The three
crystal forms of VDAC, in cymal-5 (PDB: 2JK4, [16]) and in β- and α-
DDM, have the same space group and similar unit cell dimensions
(Table 1) suggesting comparable crystal packing. The VDAC structures
published so farwere based onproteins expressed in E. coli as inclusion
bodies. The studies had to overcome several bottlenecks; the
optimization of the refolding [19], two- and three-dimensional
crystallization from refolded proteins [13], and obtention of X-ray
diffracting crystals [34]. VDAC is one of the few cases of membrane
protein crystallized after a refolding procedure [35]. Comparatively,
our method has given interesting crystals in β-DDM, in more or less
one year essentially due to the limited number of steps that have to be
optimized. This difference in time scale is important to consider for
future expression/puriﬁcation/structural studies of other membrane
proteins. Moreover, VDAC produced in cell-free expression system is
highly stable over time and against proteases (Fig. 2a). This is
consistent with the behavior of the native VDAC extracted from
mitochondria and of porins in general. Therefore, our approach
allowed the production of well-behaving membrane protein usable
for crystallization and comparable to the native one, which is of high
interest for structure/function relationships studies.
5. Conclusion
Cell-free expression system has been successfully used to solve
structures of soluble proteins [36]. The strategy that we developed led
to the successful crystallization of a cell-free expressed membrane
protein: the human mitochondrial porin VDAC. Cell-free expression
led to reproducible results in a short period of time, on a protein for
which production and crystallizationwere shown to be a difﬁcult task.
1546 A. Deniaud et al. / Biochimica et Biophysica Acta 1798 (2010) 1540–1546The strategy described herein should certainly be extended to other
membrane proteins as an alternate approach.
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